Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1392&sort=-other_investigators
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-other_investigators", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=-other_investigators", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=-other_investigators", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=-other_investigators" }, "data": [ { "type": "Grant", "id": "10510", "attributes": { "award_id": "1F31AG077931-01", "title": "Impacts of SARS-CoV-2 Infection and Age on Musculoskeletal Health", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 8478, "first_name": "John", "last_name": "Williams", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2025-08-31", "award_amount": 39019, "principal_investigator": { "id": 26516, "first_name": "Olatundun", "last_name": "Awosanya", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1621, "ror": "", "name": "INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS", "address": "", "city": "", "state": "IN", "zip": "", "country": "United States", "approved": true }, "abstract": "The Coronavirus Disease 2019 (COVID-19) pandemic as of June 14, 2021, has totaled 176.02 million cases, 3.80 million deaths, and 2.37 billion vaccine doses have been administered globally. However, many have suffered prior to the vaccine and have survived or will still suffer without the vaccine. Therefore, determining the possible long-term health ramifications post-infection, how they vary based on age at the time of infection, and whether disease severity differentially impacts long-term health is imperative. Information on how COVID-19 affects bone metabolism and homeostasis is limited. This is of crucial concern because the aging population generally has higher bone loss and are at the highest risk of developing severe COVID-19 infection. The objective of the current application is to determine whether long-term deficits in bone mass are experienced following SARS-CoV-2 infection. The long-term goal is to develop potential treatment strategies to combat COVID-19 related bone loss. Preliminary studies showed that in a K18-hACE2 mouse model of COVID-19, surviving mice infected with 1x103 or 1x104 PFU exhibited up to a 24% reduction in trabecular bone volume fraction just 2 weeks post infection (p<0.001). Infected mice had a 63% increase in osteoclast numbers (p<0.0002) and a 30% increase in surface occupied by osteoclasts (p<0.02) compared to non-infected controls. Additionally, mice infected with any dose of SARS-CoV-2 had a 40% increase in megakaryocytes (MKs) within their femoral bone marrow compared to that observed in mock-infected controls (p<0.008). Further, previously conducted studies showed that MKs regulate bone mass and osteoclast (OC) formation (aged MKs increase OCs and have increased RANKL expression). Moreover, patients with severe forms of COVID-19 have upregulated expression of numerous cytokines and growth factors which is known as an inflammatory cytokine storm. Many of these cytokines, including IL-6 and TNF-α, are known to regulate OCs and/or MKs and may be responsible for the bone loss observed in the preliminary studies. Based on these observations it is hypothesized that i) SARS-CoV-2 infection results in long-term health complications in the musculoskeletal system, and ii) SARS-CoV-2 infection and the associated cytokine storm increases MK- stimulated OC formation. To test this hypothesis, two specific aims will be pursued: 1- determine whether following SARS-CoV-2 infection the bone loss observed remains over time and whether age at the time of infection impacts the severity of bone loss induced by SARS-CoV-2 infection, and: 2- investigate the mechanisms by which OC formation and bone resorption are increased as a consequence of SARS-CoV-2 infection and age, including the extent to which MKs from infected mice induce OC formation and bone resorption. The successful completion of these studies will deepen the understanding of the health implications post-infection with SARS-COV-2 and will demonstrate how disease severity, age, and MKs influence skeletal homeostasis as well as OC formation and resorption.", "keywords": [ "2019-nCoV", "Age", "Age-Months", "Area", "Autopsy", "Blood Platelets", "Body Weight", "Bone Marrow", "Bone Resorption", "Brain", "COVID-19", "COVID-19 complications", "COVID-19 impact", "COVID-19 pandemic", "COVID-19 patient", "COVID-19 severity", "CXCL10 gene", "Cardiac", "Cells", "Cessation of life", "Clinical", "Conditioned Culture Media", "Contracts", "Data", "Disease", "Disease model", "Dose", "Elderly", "Epidemic", "Exhibits", "General Population", "Goals", "Growth Factor", "Health", "Heart", "Histologic", "Homeostasis", "Human body", "Infection", "Inflammatory", "Interleukin-1 beta", "Interleukin-17", "Interleukin-6", "K-18 conjugate", "Laboratories", "Lead", "Light", "Lung", "Megakaryocytes", "Monitor", "Mus", "Musculoskeletal", "Musculoskeletal System", "OSTF1 gene", "Organ", "Osteitis", "Osteoclasts", "Osteoporosis", "Patients", "Platelet Count measurement", "Population", "Posture", "Reporting", "SARS-CoV-2 infection", "SARS-CoV-2 negative", "Serum", "Severities", "Severity of illness", "Skeleton", "Surface", "System", "TNF gene", "TNFSF11 gene", "Testing", "Thrombophilia", "Thrombopoietin", "Thrombus", "Time", "Transgenic Mice", "Vaccines", "Viral Load result", "aged", "aging population", "base", "body system", "bone", "bone loss", "bone mass", "bone metabolism", "bone turnover", "cohort", "combat", "cytokine", "cytokine release syndrome", "experience", "high risk", "mortality", "mouse model", "osteoclast progenitor", "post SARS-CoV-2 infection", "severe COVID-19", "skeletal", "substantia spongiosa", "treatment strategy" ], "approved": true } }, { "type": "Grant", "id": "10511", "attributes": { "award_id": "1U01CK000671-01", "title": "Midwest Virtual Laboratory of Pathogen Transmission in Healthcare Settings (MVL-PATHS)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2025-09-29", "award_amount": 299761, "principal_investigator": { "id": 26517, "first_name": "Majid", "last_name": "Bani Yaghoub", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 753, "ror": "", "name": "UNIVERSITY OF MISSOURI KANSAS CITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "Midwest Virtual Laboratory of Pathogen Transmission in Healthcare Settings (MVL-PATHS) Project Summary Antimicrobial Resistant (AMR) pathogens have become a significant public health threat. Also, the COVID-19 pandemic has further revealed disparities in healthcare settings. By developing and implementing novel mathematical and computation models, the long-term goals are to optimize AMR control and preventive interventions and to improve the health equity. The central hypothesis is that the outputs of mathematical and computation models will provide optimized and effective guidelines to reduce the threat of AMR pathogen spread and reduce health disparities in healthcare settings. The rationale underlying this project is to fill the critical gap in modeling workforce capacity and develop a new generation of mathematical models for healthcare research. The central hypothesis will be tested by pursuing three specific aims to develop and employ a, (i) One Health modeling approach to understand the source, distribution and spread of AMR Enterobacteriaceae with a focus on Extended- spectrum beta-lactamase (ESBL)-producing E. coli, (ii) a novel Real-Time modeling approach to identify AMR pathogen transmission by asymptomatic spreaders and contaminated medical devices in hospitals, (iii) a novel Agent-Based Nested modeling approach to identify the effects of caregivers as vectors of disease spread, and effects of limited staffing and specialized care on equitable quality of care in nursing homes. We will pursue these aims using an innovative combination of mathematical and computational modeling techniques. These include both recently developed techniques of including human behavior in models and more-established techniques that have been applied very little to the study of health equity and AMR pathogen spread. The workforce development objectives of this proposal are to (i) enhance mathematical and computational modeling research capabilities of the public health workforce and (ii) increase the number of junior modeling professionals that are trained and experienced in modeling transmission of pathogens in healthcare settings partly incorporated with health disparities. The expected outcomes of this work are the successful training of five predoctoral fellows and creating a virtual laboratory of enhanced mathematical models to identify strategies for reducing the threat AMR pathogen spread and reducing health disparities. The results will have an important positive impact immediately because the virtual laboratory can also be used by healthcare professionals to further investigate the drivers of disease spread and estimate the relative benefits of multiple control and prevention strategies in a timely and cost-effective manner. In addition, the research outputs of this project will expand and strengthen national one-health efforts to combat resistance and will have a direct impact on CDC and its public health partners’ ability to reduce the costs, morbidity and mortality of healthcare associated infections.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10513", "attributes": { "award_id": "1P01HD109907-01", "title": "Growing up in a digital world: A synergistic approach to understanding media use in children ages 1-8 years", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-09", "end_date": "2025-08-31", "award_amount": 103806, "principal_investigator": { "id": 26518, "first_name": "RACHEL F.", "last_name": "BARR", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 181, "ror": "https://ror.org/05vzafd60", "name": "Georgetown University", "address": "", "city": "", "state": "DC", "zip": "", "country": "United States", "approved": true }, "abstract": "Progress in understanding the effects of media exposure on child outcomes has been limited by the lack of large and representative longitudinal datasets, the difficulty of tracking quality of content in an ever-changing media environment, and the lack of a mechanism to rapidly share and analyze results in a theoretically driven manner. The overarching goal of this P01 proposal is to examine trajectories of media use - characterizing the context, content, and problematic uses of media - in a diverse group of 1200 children aged 1 to 7 years and examining temporal associations with emotion regulation and social competence using a cohort sequential design. The admin core will collate and integrate the Comprehensive Assessment of Family Media Exposure (CAFE) Toolkit data along with emotion regulation and social competence outcome data across the three studies. The CAFE Toolkit measures household media use through a web-based questionnaire, time-use diary, and passive-sensing app installed on family mobile devices (Barr et al., 2020; Radesky et al., 2020b). The administrative core will manage the data integration of the three longitudinal studies across the entire age range (1-3, 3-5, 5-7 year olds). Data collected from new cohorts will be compared to data collected before and during the COVID pandemic by the same research groups using the same CAFE Toolkit to examine how media exposure patterns varied as a function of the pandemic and how those experiences are related to socio- emotional outcomes. The P01 will also develop methods to increase the efficiency of coding the quality of media content, a bottleneck in the field. Finally, the data will be integrated, shared, visualized, and analyzed in a shared analytic Research Hub. 1", "keywords": [ "2 year old", "3 year old", "7 year old", "Address", "Age", "Books", "COVID-19 pandemic", "Child", "Code", "Complex", "Data", "Data Analyses", "Data Analytics", "Data Set", "Databases", "Ecology", "Environment", "Family", "Goals", "Grant", "Household", "Infrastructure", "Joints", "Libraries", "Longitudinal Studies", "Measures", "Methods", "Online Systems", "Outcome", "Pattern", "Postdoctoral Fellow", "Predisposition", "Process", "Psychosocial Stress", "Questionnaires", "Reproducibility", "Research", "Research Personnel", "Sampling", "Science", "Secure", "Source Code", "Stream", "Surveys", "Toddler", "United States National Institutes of Health", "Variant", "aged", "analytical tool", "cohort", "coronavirus disease", "data cleaning", "data integration", "data management", "data repository", "data reuse", "data sharing", "data streams", "data structure", "data visualization", "design", "diaries", "digital", "emotion regulation", "experience", "handheld mobile device", "indexing", "longitudinal dataset", "machine learning model", "open data", "open source", "pandemic disease", "repository", "response", "sharing platform", "social skills", "socioeconomics", "time use", "training opportunity" ], "approved": true } }, { "type": "Grant", "id": "10514", "attributes": { "award_id": "1G20AI174728-01", "title": "A Bedside-to-Bench Approach to Pandemic Preparedness", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 24445, "first_name": "Nancy G.", "last_name": "Boyd", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-16", "end_date": "2024-02-29", "award_amount": 3906967, "principal_investigator": { "id": 26522, "first_name": "KENNETH W.", "last_name": "BAYLES", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 628, "ror": "https://ror.org/00thqtb16", "name": "University of Nebraska Medical Center", "address": "", "city": "", "state": "NE", "zip": "", "country": "United States", "approved": true }, "abstract": "The clinical capabilities of the University of Nebraska Medical Center (UNMC) and its clinical partner, Nebraska Medicine (NM), played vital roles in the treatment of U.S. citizens infected with Ebola in 2014 and the early response to the COVID-19 pandemic. While the presence of the National Quarantine Unit (NQU) and the Nebraska Biocontainment Unit (NBU) on campus provided UNMC researchers with some of the earliest access to individuals exposed to infectious agents (in the NQU), as well as those who begin to develop disease (in the NBU), we recognized a key gap in our capabilities is the lack of modern technologies within our high- containment spaces required to gain greater insights into the pathogenic mechanisms utilized by new and emerging pathogens. Therefore, the overall goal of this proposed project is to modernize our high-containment research laboratories to maximize their research potential and to leverage our clinical expertise to foster research on vaccine and therapeutic development. This will be achieved in two ways: First, we will improve our biocontainment infrastructure within key biocontainment research facilities in a way that increases our capacity to conduct research on high-consequence pathogens, maximizes synergy between the various biocontainment laboratories, and increases biosecurity. Second, we will invest in the modern technologies needed in our BSL-3 and ABSL-3 laboratories to conduct cutting-edge studies on new and emerging pathogens and to address critical questions related to disease pathogenesis. Upon completion, these improvements will foster much greater synergy between the clinical and research arms of UNMC and NM, leveraging early access to clinical data/samples to streamline research into disease pathogenesis, and to accelerate the development of new vaccines and therapeutics during future pandemics.", "keywords": [ "Address", "Animal Model", "COVID-19 pandemic", "Cell Separation", "Cell physiology", "Clinical", "Clinical Data", "Clinical Research", "Communicable Diseases", "Containment", "Decontamination", "Development", "Diagnostic", "Disease", "Ebola", "Enhancement Technology", "Environment", "Equipment", "Event", "Exposure to", "Faculty", "Fostering", "Future", "Goals", "Human Resources", "Individual", "Infection", "Infectious Agent", "Infectious Diseases Research", "Infrastructure", "Investments", "Laboratories", "Laboratory Research", "Medical center", "Medicine", "Microscopy", "Modernization", "Nebraska", "Pathogenesis", "Pathogenicity", "Patients", "Play", "Quarantine", "Research", "Research Personnel", "Role", "Sampling", "Standardization", "Technology", "Universities", "Update", "Work", "arm", "bench to bedside", "biocontainment facility", "biosecurity", "diagnostic assay", "emerging pathogen", "high efficiency particulate air filter", "improved", "insight", "interoperability", "laboratory development", "novel diagnostics", "novel therapeutics", "novel vaccines", "pandemic disease", "pandemic preparedness", "pathogen", "recruit", "research facility", "response", "synergism", "therapeutic development", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "10516", "attributes": { "award_id": "1R21AI169362-01A1", "title": "Where there is no death certificate: Using artificial intelligence to detect high-casualty epidemics from satellite imagery of burial sites - Resubmission - 1", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 12912, "first_name": "Misrak", "last_name": "Gezmu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-12", "end_date": "2024-08-31", "award_amount": 276776, "principal_investigator": { "id": 26279, "first_name": "Anna", "last_name": "Bershteyn", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 832, "ror": "", "name": "NEW YORK UNIVERSITY SCHOOL OF MEDICINE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Detecting high-casualty epidemics is essential for health authorities to prospectively reduce disease spread and retrospectively address health conditions in an epidemic’s aftermath – which for infectious diseases can include cancer, diabetes, neurodevelopmental disorders, “long COVID,” and other sequelae. Unfortunately, many low- and middle-income countries (LMICs) lack data systems for epidemic detection, and thus are ill- equipped to mobilize resources to reduce the spread of epidemics and address their health effects. The COVID-19 pandemic saw some of the first efforts to detect mortality during an epidemic using satellite imagery of burial sites. Though successful, these were small “one-off” efforts because manual analysis of satellite imagery is extremely labor-intensive. We propose to develop an algorithm for fully-automated measurement of burial site occupancy using satellite imagery. Our exploratory research will focus on Tanzania, which typifies a high-priority use case for such an algorithm because it was hard-hit by the two deadliest pandemics of the past century – HIV/AIDS and COVID-19 – and has not officially reported COVID-19 statistics since May 2020. Our algorithm will act upon already-collected satellite imagery, which can be obtained for any given area of Tanzania – and, indeed, the world – dating no more than two weeks back. In Aim 1, we will develop a region- based convolutional neural network (R-CNN) to automatically count the occupancy of burial sites using the most current available imagery. We will manually label burial plots in images for algorithm training and testing, and will validate the labeling with field visits to count the true occupancy of burial sites. In Aim 2, we will develop a novel “spot-the-difference” CNN (SD-CNN) to compare occupancy in earlier vs. later imagery of the same site. We hypothesize that the SD-CNN will be more accurate than the R-CNN because the algorithm would have information about what a site looked like at an earlier time-point and can be trained to notice new burial plots while ignoring “background” changes such as lighting and vegetation. We again train and test the algorithm using labeled imagery and will validate our labeling with field visits in which we will observe date markers on burial plots. Finally, in Aim 3, we will test the ability of the algorithm to identify changes in mortality due to epidemics. In Tanzania we expect burial sites to show a rise in mortality due to HIV/AIDS, a fall due to scale-up of HIV treatment, and an abrupt rise due to COVID-19. Our preliminary observations of satellite data confirm marked increases in burial site occupancy in Tanzania over the year 2020 relative to 2019. If successful, our algorithm will enable the world’s first low-cost, scalable, and globally equitable epidemic detection platform. Retrospectively, our research could help to identify areas hardest-hit by COVID-19, helping LMICs to marshal much-needed funding to address the pandemic’s aftermath. Prospectively, our research could help to keep humanity safer from future pandemics, especially those that arise in LMICs and may otherwise go undetected or unreported until it is too late.", "keywords": [ "AIDS/HIV problem", "Address", "Africa South of the Sahara", "Algorithmic Analysis", "Algorithms", "Architecture", "Area", "Artificial Intelligence", "Back", "Bereavement", "Burial", "COVID-19", "COVID-19 pandemic", "Cessation of life", "Communicable Diseases", "Containment", "Country", "Data", "Data Collection", "Data Reporting", "Data Sources", "Death Certificates", "Detection", "Diabetes Mellitus", "Disasters", "Disease", "Epidemic", "Event", "Foundations", "Funding", "Future", "Gold", "Growth", "HIV", "Health", "Image", "Imagery", "Information Systems", "Infrastructure", "Label", "Lighting", "Location", "Long COVID", "Malignant Neoplasms", "Manuals", "Marshal", "Measurement", "Methods", "Nature", "Neurodevelopmental Disorder", "Patients", "Performance", "Population", "Poverty", "Process", "Reporting", "Research", "Resolution", "Resources", "Savings", "Site", "Spottings", "Tanzania", "Testing", "Time", "Training", "Trauma", "Validation", "Visit", "Work", "Yemen", "algorithm training", "artificial intelligence algorithm", "authority", "base", "convolutional neural network", "cost", "design", "detection platform", "falls", "food insecurity", "health care service utilization", "health care settings", "health disparity", "image processing", "improved", "innovation", "long-term sequelae", "low and middle-income countries", "machine vision", "mortality", "neural network algorithm", "novel", "pandemic disease", "performance tests", "prevent", "prospective", "scale up", "statistics", "success", "tool", "transfer learning" ], "approved": true } }, { "type": "Grant", "id": "10517", "attributes": { "award_id": "1C06OD034042-01", "title": "Meharry HIV/AIDS Research and Training Facility", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 11602, "first_name": "GUANGHU", "last_name": "Wang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-16", "end_date": "2027-05-31", "award_amount": 2000000, "principal_investigator": { "id": 26526, "first_name": "Vladimir", "last_name": "Berthaud", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 938, "ror": "https://ror.org/00k63dq23", "name": "Meharry Medical College", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true }, "abstract": "The goal of the proposed HIV/AIDS Research and Training Facility grant is to renovate and develop the a cutting-edge and modern HIV research space at the Meharry Medical College (MMC). Meharry is one of the nation's oldest and largest private, historically Black academic health sciences centers. Since 1876, Meharry has been dedicated in educating healthcare professionals and biomedical scientists with a singular mission of addressing health inequities of underserved populations. For instance, MMC is playing a vital role in combatting the COVID-19 pandemic by spearheading the operations of the testing sites in Nashville and Davidson County in Tennessee (TN). MMC also conducted the adult and pediatric clinical trials of COVID-19 vaccines in minority populations. Importantly, the Meharry Center for AIDS Health Disparities Research (CAHDR), established in 2005 through NIH support, has been a leader in HIV/AIDS research and training of minority scientists, physicians, students, fellows and trainees. The scientific focus of the CAHDR is to identify, understand, and eliminate factors responsible for the profoundly disproportionate burden of HIV/AIDS among minority populations. The Center is charged to reduce the burden of AIDS in local minority communities through basic, clinical, and translational research. The HIV/AIDS-focused research environment at MMC has also been facilitated by the Meharry AIDS Center of Excellence clinic at the Meharry Community Wellness Center (MCWC). Both the CAHDR and MCWC are part of the TN Center for AIDS Research (TN-CFAR), a multi-institutional collaborative center involving Vanderbilt University Medical Center (VUMC), MMC, the TN Department of Health and Nashville CARES. Additionally, our HIV/AIDS research and training environment is also enriched by our long-standing partnership with VUMC through the Meharry Vanderbilt Alliance (MVA). Therefore, the proposed HIV/AIDS Research and Training Facility will allow us to further leverage our existing partnerships to emerge as a global leader in HIV/AIDS health disparities research and training. Currently, there are only four laboratories that are physically located within the CAHDR and several other HIV/AIDS investigators are housed in other buildings. This physical separation between our HIV/AIDS investigators poses barriers for interaction, training, access, and collaboration. Furthermore, our current lack of modern and cutting-edge laboratory space and facility severely impedes our ability to attract new faculty to the CAHDR. To address these gaps, this proposal outlines the development of cutting-edge HIV/AIDS laboratory facility adjacent to the CAHDR that will include space for four to six new investigators in an open lab space format. Together, this renovation proposal will provide unprecedented opportunity to bring all Meharry HIV/AIDS researchers to the CAHDR Floor and expand our HIV/AIDS research program into cutting-edge new areas. Most importantly, a modern and cutting-edge HIV research space will allow us to prepare and increase the number of underrepresented minority (URM) and Black, Indigenous, and People of Color (BIPOC) researchers participating in HIV-focused research.", "keywords": [ "AIDS/HIV problem", "Academic Medical Centers", "Acquired Immunodeficiency Syndrome", "Address", "Adult", "Area", "Basic Science", "Black race", "Black Indigenous People of Color", "COVID-19 pandemic", "COVID-19 vaccine", "Charge", "Childhood", "Clinic", "Clinical Research", "Clinical Trials", "Collaborations", "Communities", "County", "Development", "Environment", "Faculty", "Floor", "Goals", "Grant", "HIV", "Health", "Health Disparities Research", "Health Professional", "Health Sciences", "Laboratories", "Minority Groups", "Mission", "Modernization", "Physicians", "Play", "Privatization", "Research", "Research Personnel", "Research Training", "Role", "Site", "Students", "Tennessee", "Testing", "Training", "Translational Research", "Underrepresented Minority", "Underserved Population", "United States National Institutes of Health", "Wellness Center", "biomedical scientist", "health inequalities", "laboratory facility", "medical schools", "minority communities", "minority scientist", "operation", "physical separation", "programs" ], "approved": true } }, { "type": "Grant", "id": "10518", "attributes": { "award_id": "1R56HL160907-01", "title": "Increasing the Success of ARDS Therapeutic Clinical Trials: Novel Trial Design and Targeting of the P-selectin Pathway", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22454, "first_name": "GUOFEI", "last_name": "Zhou", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-19", "end_date": "2023-08-31", "award_amount": 529354, "principal_investigator": { "id": 26527, "first_name": "Christian", "last_name": "Bime", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 438, "ror": "https://ror.org/03m2x1q45", "name": "University of Arizona", "address": "", "city": "", "state": "AZ", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic has dramatically highlighted the serious unmet needs of acute respiratory distress syndrome (ARDS) including the lack of key genetic insights into ARDS susceptibility and health disparities, and the absence of effective FDA-approved pharmacologic interventions that address ARDS mortality. ARDS phenotype heterogeneity, the complexity of dysregulated inflammation, and the absence of predictive biomarkers have all contributed to failed ARDS therapeutic clinical trials. We previously identified a missense genetic variant, (Met62Ile) located in the selectin P ligand gene (SELPLG), which encodes for P-selectin glycoprotein ligand 1 (PSGL1) that was associated with increased susceptibility to ARDS in Blacks. PSGL1/P-selectin interactions are a highly biologically-plausible target for ARDS therapies due to the critical role of this inflammatory pathway in polymorphonuclear (PMN) leukocyte trafficking, platelet aggregation, and thrombosis. In published studies, SELPLG expression was significantly increased with ventilator (VILI)- and lipopolysaccharide (LPS)-induced lung injury that was significantly attenuated by either SELPLG knock down or PSGL1 inhibition. We have recently shown that plasma PSGL1 and P-selectin levels are significantly elevated in sepsis, ARDS, and COVID-19 pneumonia patients compared to controls. We and others have identified SELPLG and SELP variants associated with ARDS risk and mortality and SELPLG and SELP variants that are associated with elevated plasma PSGL1 and P-selectin. These preliminary data suggest that the combination of SELPLG/SELP variants with elevated plasma PSGL1/P-selectin levels may be integrated into a genetics-based biomarker risk score (GBRS) for ARDS. We speculate that a PSGL1 /P-Selectin pathway-based GBRS may define an ‘at risk’ subgroup of who are excellent candidates for inclusion in a clinical trial targeting PSGL1 /P-Selectin interactions (endotype). Focused recruitment of this “at risk” ARDS subgroup would represent a novel approach to ARDS clinical trial design. Specific Aim (SA) #1 will define the genetic regulation of plasma PSGL-1 and P-selectin levels using data and samples from the NHLBI ARDSnet ALVEOLI study (539 patients). Innovative use of Mendelian Randomization and mediation analyses will allow us to generate the genetics-based biomarker risk score for ARDS initially focusing on 10 SELPLG/22 SELP SNPs identified that potentially predict plasma PSGL1 and P- selectin levels, respectively. SA #2 will leverage biospecimens from the NIAID Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study (>1000 patients) to validate GBRS utility in predicting risk of and mortality from COVID-19-associated ARDS. SA #3 will assess the therapeutic efficacy of targeting PSGL-1/P-selectin interactions in well-established small and large animal preclinical ARDS/VILI models utilizing the FDA IND- approved P-selectin inhibitor, recombinant tandem PSGL1 immunoglobulin fusion molecule (TSGL-Ig). Successful completion of this highly translational R01 grant will generate a novel ‘point of care’ pharmacogenetic enrichment tool to be leveraged in innovatively designed human ARDS clinical trials of TSGL-Ig.", "keywords": [ "2019-nCoV", "Acute Respiratory Distress Syndrome", "Address", "Animals", "Attenuated", "Binding Sites", "Biological Markers", "Black Populations", "COVID-19", "COVID-19 mortality", "COVID-19 pandemic", "COVID-19 pneumonia", "COVID-19/ARDS", "Clinical Trials", "Clinical Trials Design", "Cohort Studies", "Critical Care", "Critical Illness", "Data", "Data Set", "FDA approved", "Family suidae", "GTP-Binding Protein alpha Subunits Gs", "Gene Expression", "Gene Frequency", "Genes", "Genetic", "Genetic Predisposition to Disease", "Glycoproteins", "Goals", "Grant", "Heterogeneity", "Human", "Immune response", "Immunoglobulins", "Immunophenotyping", "Inflammation", "Inflammatory", "Intervention", "Leukocyte Trafficking", "Ligands", "Lipopolysaccharides", "Measurement", "Mediation", "Mendelian randomization", "Minor", "Modeling", "Morbidity - disease rate", "Mus", "National Heart Lung and Blood Institute", "National Institute of Allergy and Infectious Disease", "P-Selectin", "P-selectin ligand protein", "Pathway interactions", "Patients", "Persons", "Pharmacogenetics", "Pharmacology", "Pharmacotherapy", "Phenotype", "Plasma", "Platelet aggregation", "Play", "Pre-Clinical Model", "Predisposition", "Publishing", "Rattus", "Recombinants", "Regulation", "Resources", "Risk", "Role", "SELP gene", "Sampling", "Subgroup", "Survivors", "Systems Biology", "Therapeutic", "Therapeutic Clinical Trial", "Thrombosis", "Tidal Volume", "Treatment Efficacy", "United States National Institutes of Health", "Variant", "Ventilator", "Virus Diseases", "base", "cohort", "design", "genetic predictors", "genetic variant", "genome wide methylation", "health disparity", "in silico", "in vivo", "inhibitor", "innovation", "insight", "knock-down", "lung injury", "mortality", "mouse model", "neutrophil", "novel", "novel strategies", "novel therapeutic intervention", "patient subsets", "point of care", "pre-clinical", "predictive marker", "promoter", "recruit", "sepsis induced ARDS", "success", "therapeutic target", "tool", "trafficking", "transcription factor", "trial design", "validation studies" ], "approved": true } }, { "type": "Grant", "id": "10519", "attributes": { "award_id": "1R43IP001195-01", "title": "mRNA-BASED VACCINE AGAINST MULTIPLE COVID-19 VARIANTS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2023-09-29", "award_amount": 252010, "principal_investigator": { "id": 26528, "first_name": "Mohammed", "last_name": "Bouziane", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1937, "ror": "", "name": "SUNOMIX THERAPEUTICS", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Over the last 25 months humanity has been confronting COVID-19 pandemic caused by the new Corona Virus 2 (SARS-CoV-2) infection. Mutations and deletions often occur in the genome of SARS-CoV-2 (predominantly in the Spike protein) resulting in more transmissible and pathogenic “variants of concern” (VOCs). Our long- term goal is to develop a potent COVID-19 vaccine to stop/reduce SARS-CoV-2 infections and/or COVID-19 disease caused by multiple VOCs. Major gaps: Out of the 50 mutations that occur in the genome of OMICRON variant, 32 mutations are concentrated in the Spike protein sequence alone. Because most mutation and deletion that produced the 20 known VOCs are mostly concentrated on the Spike protein sequence, there is a risk that some of current COVID-19 sub-unit vaccines, that used mainly the Spike protein as antigen, fail to protect against future VOCs despite inducing strong virus-specific neutralizing antibodies. This emphasizes two major gaps in knowledge: The need to design alternative second-generation coronaviruses vaccines that (1) will include non- structural epitopes and antigens (Ags), other than the Spike protein; and (2) will incorporate conserved B and T cell epitopes to induce cell-mediated immune responses (in addition to humoral responses). Preliminary Results: We: (1) Identified potential human T cell target epitopes (the part of a virus antigens that the immune system recognizes) from the whole SARS-CoV-2 genome; and (2) Produced a first prototype multi-epitope COVID-mRNA vaccine candidate using the scalable and proven mRNAs vaccine platform, and (3) Generated a novel “humanized” susceptible HLA-DR/HLA-A*0201/hACE2 triple transgenic mouse model in which to test additional COVID-mRNA-based vaccine candidates. We hypothesize that one of our 5 COVID-19 vaccine candidates will protect “humanized” mice from infection and COVID-like disease caused by intranasal inoculation with SARS-CoV-2 a, b, g, d and Omicron VOCs. Our Specific Aims are: Aim 1: To construct 5 additional multi- epitopes COVID-mRNA-based vaccine candidates, that will incorporate conserved B and T cell epitopes from SARS-CoV-2 VOCs that circulate in the United Sates and other 200 other countries. Aim 2: To test in our novel “humanized” mouse model the safety, immunogenicity, and protective efficacy against SARS-CoV-2 a, b, g, d or Omicron VOCs of 5 multi-epitope COVID-mRNA vaccine candidates, delivered intranasally. The durability of protection and its correlation with blocking/neutralizing antibodies and the number and function of tissue-resident SARS-CoV-2-specific CD4+ and CD8+ TRM cells in the lungs and brains will be determined. If successful, the lead vaccine that protects against most VOCs, will be tested in non-human primate for safety (SBIR Phase II) and subsequently could be moved quickly into an FDA Phase 1 clinical trial.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10520", "attributes": { "award_id": "3U54CA260517-02S1", "title": "Admin-Core-001", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 25072, "first_name": "Yin", "last_name": "Liu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2025-08-31", "award_amount": 440000, "principal_investigator": { "id": 23528, "first_name": "Scott Dexter", "last_name": "Boyd", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "OVERALL: SUMMARY We propose the Stanford U54 SARS-CoV-2 Serological Sciences Center of Excellence (SUSS-COE) as a member of the SeroNet consortium gathered to address the urgent need for better understanding of human immune responses to the SARS-CoV-2 coronavirus pandemic that has engulfed the U.S. and the world. Our Center will be based on four scientific pillars: Deep mechanistic analysis of the adaptive immune responses of COVID-19 patients, spanning serological, B cell and T cell responses, Analysis of immune responses in the blood as well as mucosal sites, Comparing immune responses induced by infection to those induced by candidate vaccines, and Studying medically underserved, underrepresented and at-risk patient populations Within these parameters, we will attempt to determine the factors that result in effective and durable immunity to SARS-CoV-2 infection. We are dedicated to broad collaboration, rapid sharing of data and technical knowledge, nimbleness in responding to the rapidly changing pandemic, and rapid translation of research findings to CLIA Lab clinical testing and development of new therapeutic approaches. We feel these are the best routes forward for addressing gaps in our understanding of the determinants of protective immunity to SARS-CoV-2, and providing useful tools for physicians and patients.", "keywords": [ "2019-nCoV", "Acute", "Address", "African American population", "Agonist", "Antibodies", "Antigen Targeting", "Attention", "Award", "B-Lymphocytes", "Biopsy", "Blood", "COVID-19", "COVID-19 diagnosis", "COVID-19 patient", "COVID-19 test", "Cancer Patient", "Caucasians", "Cells", "Clinical", "Collaborations", "Communities", "Convalescence", "Data", "Data Set", "Disease", "Elderly", "Evaluation", "Female", "Hispanic Americans", "Human", "Immune", "Immune response", "Immune system", "Immunity", "Immunologic Memory", "Immunologics", "Individual", "Infection", "Institution", "Knowledge", "Laboratories", "Longitudinal Studies", "Mucosal Immune Responses", "Mucous Membrane", "Nose", "Patient Recruitments", "Patients", "Peripheral Blood Mononuclear Cell", "Phenotype", "Physicians", "Plasma", "Plasma Cells", "Populations at Risk", "Prognosis", "Protocols documentation", "Research", "Risk", "Route", "SARS-CoV-2 immune response", "SARS-CoV-2 immunity", "SARS-CoV-2 infection", "Science", "Serology", "Severity of illness", "Site", "T cell response", "T-Lymphocyte", "Testing", "Tissue Sample", "Toll-like receptors", "Translational Research", "Translations", "Vaccination", "Validation", "Viral Antigens", "adaptive immune response", "adaptive immunity", "base", "clinical development", "cohort", "data sharing", "immune checkpoint blockade", "interest", "male", "medically underserved", "medically underserved population", "member", "mucosal site", "novel therapeutic intervention", "pandemic coronavirus", "pandemic disease", "patient population", "research clinical testing", "response", "tool", "vaccine candidate", "vaccine trial", "young adult" ], "approved": true } }, { "type": "Grant", "id": "10521", "attributes": { "award_id": "1G20AI174721-01", "title": "ATCC's High Containment Facility Renovations in Support of NIAID and Pandemic Preparedness", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 24445, "first_name": "Nancy G.", "last_name": "Boyd", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-16", "end_date": "2024-02-29", "award_amount": 3862721, "principal_investigator": { "id": 26529, "first_name": "Rebecca", "last_name": "Bradford", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1788, "ror": "https://ror.org/03thhhv76", "name": "American Type Culture Collection", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary: The proposed project aims to renovate ATCC's High Containment Facility (HCF) at the American Type Culture Collection (ATCC) in Manassas, Virginia. ATCC's 7,500 ft2 biocontainment facility was built in 2007 with funding from NIAID and has been dedicated to developing infectious disease strains and reagents needed to rapidly advance diagnostics, vaccines, and therapeutics against priority pathogens. Since 2003, ATCC has partnered with NIAID to centralize and provide critical scientific resources through the Biodefense and Emerging Infections Resources (BEI Resources) program. The NIAID established BEI Resources to provide the global research community with reagents, tools, and information for studying Category A, B, and C priority pathogens, emerging infectious disease agents, and other microbiological materials relevant to human health. Over the past 18 years, ATCC has provided over 1,360,000 reagents to over 14,000 investigators at 3,740 institutions in 119 countries spanning over 500 human pathogens in NIAID's priority portfolio. During this period, BEI Resources has provided critical materials for vital disease outbreaks, including H1N1, MERS, Ebola, and Zika. Over the past two years, ATCC has rapidly created more than 690 SARS-CoV-2 products; acquired, produced, and authenticated more than 165 stocks of SARS-CoV-2 for both general research and challenge studies; and shipped more than 86,000 research reagents to over 2,800 researchers in more than 70 countries for the development of countermeasures and basic research. The material provided by BEI Resources has been cited in more than 1,800 SARS-CoV-2 publications since February of 2020. In addition, ATCC has fostered collaboration and partnerships across NIAID programs and external working groups to share resources, information, and data to accelerate discoveries and harmonize scientific approaches for pandemic response and preparedness. ATCC's high containment facility houses laboratories essential for BSL-3 and Select Agent infectious disease research, product development, and large-scale reagent production for the research community. This proposal aims to renovate and upgrade the HVAC, decontamination, and security systems. The renovations also include upgrades to fixed equipment and interior finishing in the facility. The renovations will modernize the facility for use by 40 Ph.D. ATCC scientists, collaborators, and laboratory support staff. The products and services developed in the facility will support thousands of scientists globally each year to prepare and respond to pandemics. ATCC is seeking this opportunity for engagement with the NIAID to invest in this facility which has been foundational for the nation's pandemic response and preparedness.", "keywords": [ "2019-nCoV", "3-Dimensional", "Air Conditioning", "Alphavirus", "American Type Culture Collection", "Animals", "Antiviral Agents", "Basic Science", "Biological Assay", "COVID-19", "Categories", "Collaborations", "Communicable Diseases", "Communities", "Computer Security", "Containment", "Coronavirus", "Country", "Data", "Decontamination", "Development", "Diagnostic", "Dimensions", "Disease Outbreaks", "Doctor of Philosophy", "Ebola", "Ebola virus", "Emerging Communicable Diseases", "Equipment", "FDA approved", "Family", "Fostering", "Foundations", "Funding", "Goals", "Health", "Heating", "Human", "Infection", "Infectious Agent", "Infectious Diseases Research", "Influenza A Virus H1N1 Subtype", "Institution", "Laboratories", "Logistics", "Longevity", "Microbiology", "Middle East Respiratory Syndrome", "Mission", "Modernization", "National Institute of Allergy and Infectious Disease", "Orthobunyavirus", "Pathogenesis", "Peptides", "Pharmaceutical Preparations", "Production", "Protocols documentation", "Publications", "RNA", "RNA Viruses", "Readiness", "Reagent", "Regulation", "Research", "Research Personnel", "Research Support", "Resource Sharing", "Resources", "Scientist", "Services", "Ships", "System", "Therapeutic", "Translating", "Translational Research", "Vaccines", "Viral", "Virginia", "Virus", "ZIKA", "Zika Virus", "antimicrobial", "base", "biobank", "biocontainment facility", "biodefense", "emerging pathogen", "facility renovation", "human pathogen", "in vitro Model", "influenzavirus", "novel", "pandemic disease", "pandemic preparedness", "pathogen", "pre-clinical", "priority pathogen", "product development", "programs", "repaired", "response", "response biomarker", "screening", "small molecule", "square foot", "tool", "two-dimensional", "ventilation", "working group" ], "approved": true } } ], "meta": { "pagination": { "page": 1392, "pages": 1419, "count": 14184 } } }